Bridgefront Capital’s Edwards Lifesciences EW Stock Holding History

Bridgefront Capital’s Portfolio EW Stock Details EW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-10,085	Closed	-$784K	–	604
2025 Q3	$784K	Sell	10,085 -10,181	-50%	-$795K	0.23%	136
2025 Q2	$1.59M	Buy	20,266 +9,286	+85%	+$693K	0.42%	38
2025 Q1	$796K	Buy	+10,980	New	+$786K	0.23%	129
2024 Q4	–	Sell	-11,458	Closed	-$756K	–	640
2024 Q3	$756K	Buy	+11,458	New	+$832K	0.29%	90
2023 Q4	–	Sell	-16,572	Closed	-$1.15M	–	427
2023 Q3	$1.15M	Buy	+16,572	New	+$1.33M	0.8%	9
2022 Q4	–	Sell	-10,949	Closed	-$905K	–	405
2022 Q3	$905K	Buy	+10,949	New	+$1.05M	0.93%	7
2022 Q2	–	Sell	-2,815	Closed	-$331K	–	334
2022 Q1	$331K	Buy	+2,815	New	+$316K	0.41%	83
2021 Q2	–	Sell	-5,455	Closed	-$456K	–	687
2021 Q1	$456K	Buy	5,455 +1,260	+30%	+$107K	0.14%	265
2020 Q4	$383K	Buy	+4,195	New	+$348K	0.13%	287

Other funds holding EW

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Bridgefront Capital's EW Position: Q4 2025 in Review

Bridgefront Capital sold out of Edwards Lifesciences (EW) in Q4 2025, closing a stake of 10,085 shares — an estimated $784K sold.

Bridgefront Capital first reported a position in EW in Q4 2020 and held it in 9 quarters. The position peaked at $1.59M in Q2 2025. 1,313 funds tracked by Wall St. Rank hold EW as of Q4 2025.

Bridgefront Capital reported no remaining Edwards Lifesciences position as of Q4 2025 after selling out during the quarter.
Bridgefront Capital sold 10,085 Edwards Lifesciences shares in Q4 2025, an estimated $784K.
Bridgefront Capital first reported a position in Edwards Lifesciences in Q4 2020 and held it in 9 quarters.
Bridgefront Capital's Edwards Lifesciences position peaked at $1.59M in Q2 2025.
1,313 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q4 2025.

Based on Bridgefront Capital's 13F filing for Q4 2025, filed 13 Feb 2026.